ID

44154

Description

NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Keywords

Versions (5)
  1. 12/26/17 12/26/17 -
  2. 12/27/17 12/27/17 -
  3. 3/15/21 3/15/21 - Dr. rer. medic Philipp Neuhaus
  4. 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
  5. 9/20/21 9/20/21 -
Copyright Holder

Universität zu Köln

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314

German

Follow up

16 forms  
Bewertung des Patienten
Description

Bewertung des Patienten

Datum
Description

Die Dokumentation des Follow-Up erfolgt mindestens bis zur Sperrung der Datenbank zur Durchgeführung der finalen Analyse. Follow-Up Untersuchungen sollten alle 3-6 Monate durchgeführt werden.

Data type

date

Measurement units
  • mm/dd/yyyy
Alias
UMLS CUI [1]
C0011008
mm/dd/yyyy
Allgemeinzustand nach Lansky (≤ 16 Jahre) oder Karnofsky Skala*
Description

Karnofsky Performance Status

Data type

integer

Alias
UMLS CUI [1]
C0206065
Remissionsstatus
Description

Disease remission; Status

Data type

integer

Alias
UMLS CUI [1,1]
C0544452
UMLS CUI [1,2]
C0449438
Wenn verstorben: Todesdatum
Description

Date of death

Data type

date

Measurement units
  • mm/dd/yyyy
Alias
UMLS CUI [1]
C1148348
mm/dd/yyyy
Rezidiv oder Progression
Description

Relpase

Data type

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C0035020
Ort des Rezidivs/Progression
Description

Date in time; Recurrent disease

Data type

text

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0277556
Bemerkung
Description

Comment

Data type

text

Alias
UMLS CUI [1]
C0947611
Footer module
Description

Footer module

Date
Description

Date

Data type

date

Alias
UMLS CUI [1]
C0011008
Investigator name
Description

Investigator name

Data type

text

Alias
UMLS CUI [1]
C2826892
Investigator signature
Description

Investigator signature

Data type

text

Alias
UMLS CUI [1]
C2346576
Back to the top of the page

Similar models

Follow up

16 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Bewertung des Patienten
Date
Item
Datum
date
C0011008 (UMLS CUI [1])
Karnofsky Performance Status
Item
Allgemeinzustand nach Lansky (≤ 16 Jahre) oder Karnofsky Skala*
integer
C0206065 (UMLS CUI [1])
Item
Remissionsstatus
integer
C0544452 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Disease remission; Status
Code List
Remissionsstatus
CL Item
Nicht auswertbar (6)
C1883425 (UMLS CUI-1)
(Comment:de)
CL Item
Komplette Remission (CR)
C0677874 (UMLS CUI-1)
(Comment:de)
CL Item
Sehr gute partielle Remission (VGPR )
C4053871 (UMLS CUI-1)
(Comment:de)
CL Item
Partielle Remission (PR)
C1275833 (UMLS CUI-1)
(Comment:de)
CL Item
Unverändert (SD)
C0677946 (UMLS CUI-1)
(Comment:de)
CL Item
Progression (PD)
C0242656 (UMLS CUI-1)
(Comment:de)
Date of death
Item
Wenn verstorben: Todesdatum
date
C1148348 (UMLS CUI [1])
Relpase
Item
Rezidiv oder Progression
boolean
C0277556 (UMLS CUI [1])
C0035020 (UMLS CUI [2])
Date in time; Recurrent disease
Item
Ort des Rezidivs/Progression
text
C0011008 (UMLS CUI [1,1])
C0277556 (UMLS CUI [1,2])
Comment
Item
Bemerkung
text
C0947611 (UMLS CUI [1])
Item Group
Footer module
Date
Item
Date
date
C0011008 (UMLS CUI [1])
Investigator name
Item
Investigator name
text
C2826892 (UMLS CUI [1])
Investigator signature
Item
Investigator signature
text
C2346576 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial